Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729330 | 0.85 | DPP4 (0.43) | LMNAMEN1KMT2AFKBP1ACTSS | |
| SCHEMBL20718021 | 0.83 | SMN1; SMN2 (0.58) | CYP3A4OPRK1LMNAMEN1KMT2A | |
| SCHEMBL29861096 | 0.82 | SMN1; SMN2 (0.50) | LMNAMEN1KMT2APOLBCTSS | |
| SCHEMBL4187465 | 0.82 | SMN1; SMN2 (0.50) | LMNAMEN1KMT2APOLBCTSS | |
| SCHEMBL2188227 | 0.81 | ITGB3 (0.47) | OPRK1MEN1KMT2AFKBP1AITGB3 | |
| SCHEMBL2187323 | 0.80 | ITGB3 (0.47) | OPRK1MEN1KMT2AFKBP1AITGB3 | |
| SCHEMBL2186839 | 0.80 | ITGB3 (0.47) | OPRK1MEN1KMT2AFKBP1AITGB3 | |
| SCHEMBL7159219 | 0.79 | LMNA (0.63) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL4371451 | 0.79 | MEN1 (0.59) | CYP3A4OPRK1LMNAMEN1KMT2A | |
| SCHEMBL17371252 | 0.79 | MEN1 (0.49) | LMNAMEN1KMT2ACTSSRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630058-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-111630058-A | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2020-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | CYP3A4 616/4885OPRK1 2644/4885LMNA 4511/4885 |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | CYP3A4 616/4885OPRK1 2644/4885LMNA 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.